Taking functional precision medicine to the next level
In contrast to the analysis of biomarkers and genetic profiles, functional precision medicine uses the patient’s cells for direct testing of drug efficacy. Functional assays provide information in the best possible proximation of the patient’s response from a pool of multiple therapeutic options. They allow not only to determine the combination therapy with the highest probability of success, but in addition provide information of optimal drug ratio’s and potentially dosing recommendations to minimize side effects for the patient. PreComb has developed a novel technology to make efficient use of the patient’s tumor cells for drug profiling. The efficacy of tested therapies will be assayed in real-time by the most clinically relevant parameter – progression or remission of the tumor. Correlating the individual patient response to a comprehensive drug response database, the treating physician will be provided with a detailed analysis, classification and treatment proposal(s) to determine the best suitable therapies for the patient.
Any ex vivo testing aims to reflect the patient’s response as close as possible. Drug sensitivity is not only driven by genetical measures but rather by the whole tumor microenvironment. The better we can recapitulate the spatial configuration of a tumor the higher the predictive capacity of the test system. PreComb’s 3D3 technology employs microtumors which are produced directly after cell isolation from the patient’s tumor, reflecting the tumor cell composition as close as possible. Drug testing is done within 5-7 days after cell isolation in contrast to tumor organoids produced from tumor stem cells or PDX-models.
Efficient use of patient tumor tissue
Tumor material is precious and needed for routine clinical histo- and genotyping. Basically, there is only limited tumor sample available which can be used for additional in vitro diagnostic (IVD). To further open the IVD space towards patient-specific drug profiling, they must make efficient use of small amounts of tumor tissues. Microtumors can be produced with very small quantities of cells. Moreover, the 3D3 test technology does not destroy the tumor cells so that they can be used after the test for downstream analysis e.g. biomarkers or genetic profiles to further substantiate a therapeutic decision.